A key negative regulator of NF-κB signaling is cylindromatosis (CYLD) deubiquitinase (Kovalenko et al., 2003; Trompouki et al., 2003; Sun, 2010) and miR-182 is able to directly inhibit the ubiquitin binding of CYLD, a component of the NF-κB signaling pathway, thereby inducing an aggressive phenotype in glioma cells (Song et al., 2012). This evidence concerns the gene NFKB1 and glioma.